Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7-Reference-Cited by-同舟云学术

Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7

Published:2006-06-15 Issue:9 Volume:66 Page:966-970
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Mian Christine,Lodde Michele,Comploj Evi,Palermo Salvatore,Lusuardi Lukas,Marziani Fiovo,Chiocchetti Andreas,Spada Alessandra,Mian Michael,Pycha Armin

Publisher

Wiley

Subject

Urology,Oncology

Reference26 articles.

1. Linkage analysis of prostate cancer susceptibility: confirmation of linkage at 8p22–23

2. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer

3. The Role of Chromosome 8p22 Deletion for Predicting Disease Progression and Pathological Staging in Prostate Cancer

4. Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate Cancer

5. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer;Clinical Cancer Research;2009-12-22

2. Genetic profile identification in clinically localized prostate carcinoma;Urologic Oncology: Seminars and Original Investigations;2009-09

3. Molecular Pathology of the Genitourinary Tract: Prostate and Bladder;Surgical Pathology Clinics;2008-12

4. Re: Franclim R. Ribeiro, Rui Henrique, Ana T. Martins, Carmen Jerónimo and Manuel R. Teixeira. Relative Copy Number Gain of MYC in Diagnostic Needle Biopsies is an Independent Prognostic Factor for Prostate Cancer Patients. Eur Urol 2007;52:116–25;European Urology;2007-11

5. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy;Clinical Chemical Laboratory Medicine;2007-01-01